IP & Corporate Partnerships

You are using an outdated browser. Please upgrade your browser to improve your experience.

IP & Corporate Partnerships

Why Gaylord?

Gaylord Specialty Healthcare is uniquely positioned for corporate partnering based on its’ independent structure and it not being aligned with any one university, as well as its’ ability to expediently move into corporate partnerships often made difficult by larger bureaucratic health care institutions.

In 2019, Gaylord began a new mission, which is focused on also assessing the commercial opportunities that its staff and faculty may contribute to healthcare.  This initiative is undergoing continued evaluation and refinement, as we internally advance our discoveries, and as we have completed our first potential “licensing-driven” partnering agreement with a major global health care corporation.

We invite you to reach out to us for more information and to discuss potential partnering opportunities.

For Information contact:

Pete Grevelding,  VP, Clinical Operations
Phone: (203) 741-3386
Fax: (203) 679-3580
Email: pgrevelding@gaylord.org

Research at Gaylord

Background

Gaylord Specialty Healthcare’s current activities in developing intellectual property and partnering with corporate entities may in many ways be traced back to the transformational activities that occurred in the field of IP and licensing, during the 1980s.

The Bayh-Dole Act of 1980 aimed to do nothing less than transform scientific research.  For the first time, it allowed American universities to own the patents on all discoveries their faculty members had made using federal research grants. In addition, universities and related discovery engines  -- including hospitals and other health care facilities, such as Gaylord Specialty Healthcare --  could develop relationships with corporations to allow those inventions to be commercialized into products in exchange for participation in the financial benefits of discovery, specifically if federal research funds had been utilized in innovative discovery. 

It was a short eight years later, in 1988, that Henry Chauncey Jr., armed with much of the current understanding of the Bayh-Dole Act and experience in interactions between universities and corporations, was named President and Chief Executive Officer of Gaylord Specialty Healthcare.  He joined Gaylord after serving as president and chief executive officer of Science Park, founded in 1982, in New Haven, CT.   Science parks are often built in close proximity to universities and with corporate partners and academic relationships both serving as important bridges — the idea being that businesses and tech companies will benefit from “cross-pollination.”  Ideally, this new highway of communication leads to increased innovation.  In the best-case scenario, one ends up with the Stanford Industrial Park, also known as Silicon Valley. 

GROWTH AND EXPANSION

While Gaylord Specialty Healthcare has continued its’ interest in intellectual property and corporate partnering since the early transformational events in scientific research, more recently there were several events in Gaylord’s history which stressed the potential opportunities for Gaylord to provide its expertise in product development and beta testing, both independently and aligned with multiple world-class universities.

The activities included the following:

2012 Gaylord acquires the Ekso Bionic Exoskeleton to help individuals with lower-body weakness or paralysis to walk

2013 Gaylord opens the Center for Concussion Care

2014 Gaylord is designated as a Passy-Muir Center of Excellence

2015 Gaylord is designated as a Vapotherm Center of Excellence

2015 Gaylord opens the Center for Brain Health